Dataset Information


89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.

ABSTRACT: Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients benefit despite patient selection for RAS wild type (wt) tumors. Based on the hypothesis that tumor targeting is required for clinical benefit of anti-EGFR treatment, biodistribution and tumor uptake of (89)Zr-cetuximab by Positron Emission Tomography (PET), combining the sensitivity of PET with the specificity of cetuximab for EGFR was evaluated. Ten patients with wt K-RAS mCRC received 37 ± 1 MBq (89)Zr-cetuximab directly (<2 h) after the first therapeutic dose of cetuximab. PET-scans were performed from 1 hour to 10 days post injection (p.i.). Biodistribution was determined for blood and organs. Uptake in tumor lesions was quantified by Standardized Uptake Value (SUV) and related to response. In 6 of 10 patients (89)Zr-cetuximab uptake in tumor lesions was detected. Four of 6 patients with (89)Zr-cetuximab uptake had clinical benefit, while progressive disease was observed in 3 of 4 patients without (89)Zr-cetuximab uptake. Taken together, tumor uptake of 89Zr-cetuximab can be visualized by PET imaging. The strong relation between uptake and response warrants further clinical validation as an innovative selection method for cetuximab treatment in patients with wt RAS mCRC.

SUBMITTER: Menke-van der Houven van Oordt CW 

PROVIDER: S-EPMC4745807 | BioStudies | 2015-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7076055 | BioStudies
2015-01-01 | S-EPMC4770730 | BioStudies
2020-01-01 | S-EPMC7160960 | BioStudies
2020-01-01 | S-EPMC7529530 | BioStudies
2012-01-01 | S-EPMC3500677 | BioStudies
2018-01-01 | S-EPMC5950648 | BioStudies
2013-01-01 | S-EPMC4967936 | BioStudies
2019-01-01 | S-EPMC6599252 | BioStudies
2017-01-01 | S-EPMC5354801 | BioStudies
1000-01-01 | S-EPMC3637856 | BioStudies